<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03146130</url>
  </required_header>
  <id_info>
    <org_study_id>PI2016_843_0002</org_study_id>
    <nct_id>NCT03146130</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders</brief_title>
  <acronym>NoISE-PD</acronym>
  <official_title>Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders (TCI) Induced by Dopaminergic Treatments in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Impulse control disorders encountered in Parkinson's disease (PD) are induced by dopaminergic&#xD;
      medications and their frequency is estimated to be nearly 20%, mainly under dopaminergic&#xD;
      agonists (AD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Impulse control disorders encountered in Parkinson's disease (PD) are induced by dopaminergic&#xD;
      medications and their frequency is estimated to be nearly 20%, mainly under dopaminergic&#xD;
      agonists (AD). They constitute a major public health issue due to their sometimes dramatic&#xD;
      socio-occupational and judicial consequences. Most often the therapeutic strategy is to&#xD;
      reduce or even stop AD, which can lead to withdrawal symptoms, apathy or aggravation of motor&#xD;
      signs.&#xD;
&#xD;
      N-acetylcysteine (NAC) may have an interest in the treatment of ICD. This molecule reduces&#xD;
      &quot;craving&quot; in addictions by substance abuse, but also in behavioral addictions, with as a&#xD;
      potential mechanism a reduction in levels of plasma alphasynuclein.&#xD;
&#xD;
      The main objective of this randomized, double-blind, placebo-controlled, multicenter&#xD;
      controlled trial is to demonstrate that a 10-week NAC add-on treatment, compared to placebo,&#xD;
      improves the behavioral addictions of Moderate in the MP. The main endpoint will be the&#xD;
      variation of the subdivision of the hyperdopaminergic behaviors of the Ardouin Parkinson's&#xD;
      Disease Behavioral Assessment (ECMP) scale between the baseline and after 10 weeks of&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 5, 2018</start_date>
  <completion_date type="Anticipated">December 20, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the variation of the scale of the behavioral evaluation</measure>
    <time_frame>11 weeks</time_frame>
    <description>show that a 10-week treatment with N-acetylcysteine compared to placebo improves the mild-to-moderate impulse control disorders induced by dopaminergic medications in Parkinson's disease.&#xD;
The primary endpoint is the change in score from Part IV of the Ardouin Parkinson's Behavioral Assessment of Parkinson's Disease (ECMP) (ECMP IV), which evaluates hyperdopaminergic behaviors between the baseline and after 10 weeks. treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Impulse Control Disorder</condition>
  <condition>Parkinson</condition>
  <arm_group>
    <arm_group_label>Patient treated with N-acetylcysteine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomise in the drug group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient treated with placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomise in the placebo group</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Variation of behaviors of Parkinson's disease</intervention_name>
    <description>Variation of hyper dopaminergic behaviors of Parkinson's disease</description>
    <arm_group_label>Patient treated with N-acetylcysteine</arm_group_label>
    <arm_group_label>Patient treated with placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Parkinson's disease according to UKPDSBB criteria&#xD;
&#xD;
          -  Subject aged 18 to 80&#xD;
&#xD;
          -  Presence of a mild to moderate impulse control disorder defined by an ECD&#xD;
             hyperdopaminergic sub-score (part IV) between 3 and 22 associated with the&#xD;
             investigator's assessment&#xD;
&#xD;
          -  MMSE â‰¥ 24&#xD;
&#xD;
          -  Ongoing treatment with dopaminergic agonist and / or levodopa&#xD;
&#xD;
          -  No change in antiparkinsonian and / or psychotropic treatment in the month preceding&#xD;
             inclusion&#xD;
&#xD;
          -  Expected stability of antiparkinsonian and / or psychotropic treatment during the&#xD;
             study period&#xD;
&#xD;
          -  Informed patient consent&#xD;
&#xD;
          -  Patient supported by social security&#xD;
&#xD;
          -  Presence of a caregiver&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe TCI defined by a hyperdopaminergic sub-score at ECMP (part IV) greater than 23&#xD;
             associated with the investigator's assessment&#xD;
&#xD;
          -  Patient with TCI suspected of having serious legal and / or relationship problems&#xD;
             during the study period&#xD;
&#xD;
          -  Adaptation of the anti-parkinsonian and / or psychotropic treatment (cf section 6.2)&#xD;
             probably necessary during the duration of the study&#xD;
&#xD;
          -  Patient treated with naltrexone, amantadine, antipsychotic in the 6 weeks prior to&#xD;
             inclusion&#xD;
&#xD;
          -  Patient under tutorship or curatorship&#xD;
&#xD;
          -  History of hypersensitivity to any of the components or to any of the excipients&#xD;
&#xD;
          -  Fructose intolerance, glucose-galactose malabsorption syndrome or sucrase / isomaltase&#xD;
             deficiency&#xD;
&#xD;
          -  Gastrointestinal duodenal ulcer in progress&#xD;
&#xD;
          -  Pregnancy, breastfeeding&#xD;
&#xD;
          -  Patients with contra-indicated treatments in association with NAC&#xD;
&#xD;
          -  Patient with phenylketonuria&#xD;
&#xD;
          -  Patients with proven difficulty in expectorating&#xD;
&#xD;
          -  Patients with an asthmatic risk that can lead to bronchospasm&#xD;
&#xD;
          -  Patients with intolerance to histamine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melissa TIR, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU AMIENS-PICARDIE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa TIR, Dr</last_name>
    <phone>+33322667987</phone>
    <email>tir.melissa@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <state>Picardie</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa TIR, Dr</last_name>
      <phone>+33322667987</phone>
      <email>tir.melissa@chu-amiens.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 3, 2017</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <last_update_submitted>August 3, 2018</last_update_submitted>
  <last_update_submitted_qc>August 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Disruptive, Impulse Control, and Conduct Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

